title: An investigational ovarian stimulation protocol increased significantly the psychological burden in women with premature ovarian failure.
abstract: OBJECTIVE
  To assess the psychological impact (Hospital Anxiety and Depression Scale) of an investigational ovarian stimulation protocol in women with premature ovarian failure (POF).
  
  
  METHODS
  Prospective longitudinal study.
  
  
  METHODS
  Ten women with POF.
  
  
  METHODS
  Women with idiopathic POF were placed on three consecutive treatment cycles consisting of gonadotropin ovarian stimulation after estrogen priming, gonadotropin-releasing hormone agonist pituitary desensitization, and corticosteroid immune suppression.
  
  
  RESULTS
  Median anxiety and depression scores increased significantly from baseline following three consecutive treatment cycles from 4.0 (range 2.0-8.0) to 11.0 (range 10.0-14.0) (p-value 0.041) and from 1.5 (range 0-6.0) to 9.0 (range 7.0-10.0) (p-value 0.039), respectively. There were nine "probable" anxiety (90%) and three "probable" depression (30%) cases on the final treatment cycle compared with none (0%) on baseline (p-value 0.004 and 0.250, respectively).
  
  
  CONCLUSIONS
  The use of investigational ovarian stimulation protocols in women with idiopathic POF was associated with excessive psychological strain. Women with POF should be cautioned against the potentially harmful aspect of similar treatments of unproven benefit.
authors.affiliation: Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Beirut, Lebanon.
authors.forename: Johnny T
authors.initials: JT
authors.lastname: Awwad
authors.forename: Ghina S
authors.initials: GS
authors.lastname: Ghazeeri
authors.forename: Antoine
authors.initials: A
authors.lastname: Hannoun
authors.forename: Keith
authors.initials: K
authors.lastname: Isaacson
authors.forename: Michel
authors.initials: M
authors.lastname: Abou-Abdallah
authors.forename: Chantal G
authors.initials: CG
authors.lastname: Farra
mesh_terms: D000293:Adolescent; D000328:Adult; D001007:Anxiety / Q000209:etiology; D002064:Buserelin / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D003863:Depression / Q000209:etiology; D004967:Estrogens / Q000627:therapeutic use; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000523:psychology / Q000628:therapy*; D007315:Insemination, Artificial; D008137:Longitudinal Studies; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D008596:Menotropins / Q000627:therapeutic use; D010053:Ovary / Q000000981:diagnostic imaging; D010062:Ovulation Induction; D011241:Prednisone / Q000627:therapeutic use; D016649:Primary Ovarian Insufficiency / Q000150:complications / Q000523:psychology*; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D012102:Reproductive Control Agents / Q000627:therapeutic use; D014463:Ultrasonography; D055815:Young Adult
chemical_list: D006063:Chorionic Gonadotropin; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D005938:Glucocorticoids; D012102:Reproductive Control Agents; D008596:Menotropins; D017258:Medroxyprogesterone Acetate; D002064:Buserelin; D011241:Prednisone